Title: Efficacy and mechanism of thyroxine treatment on pregnancy and neonatal outcomes in women with thyroid antibodies:
Funder: Medical Research Council

Abstract: Scientific Abstract|We conducted a systematic review exploring the association between thyroid antibodies and adverse pregnancy outcomes. For miscarriage, we identified 29 studies (9817 women), and 26 of these showed a positive association. Meta-analysis of the 29 studies showed more than doubling in the odds of miscarriage in the presence of thyroid antibodies (OR:2.4, 95% CI: 1.9, 3.1). For preterm birth, we identified 4 studies (2896 women). All studies showed a positive association and meta-analysis found more than doubling in the odds of preterm birth in the presence of thyroid antibodies (OR: 2.7, 95% CI: 1.9, 3.9). The two dominant hypotheses for these observations are that a) thyroid antibodies represent a state of global immune dysfunction and b) thyroid antibodies are associated with relative thyroid insufficiency. There is evidence that thyroxine treatment can alter global immune response directly, and it can also correct any relative thyroid insufficiency. We carried out another systematic review to identify studies of thyroxine replacement to improve pregnancy outcomes in women with thyroid antibodies: two randomised trials, including a total of 187 women, were identified; the studies showed a reduction in miscarriages (RR: 0.48, 95% CI:0.25, 0.92) and preterm birth (RR:0.31; 95% CI:0.11, 0.90) with levothyroxine treatment. However, our UK clinician survey (n=183) found that only 8% (15/183) of clinicians use or intend to use levothyroxine for the prevention of miscarriages in thyroid antibody positive women and that 85% (155/183) do not currently use levothyroxine, but would be willing to recruit into a randomised study.|We, therefore, propose a randomised, placebo-controlled, double-blind, multi-centre trial to test the hypothesis that in euthyroid women with thyroid peroxidase antibodies, levothyroxine (50mcg, oral, once daily), started pre-conceptually and continued to the end of pregnancy, compared with placebo, increases live births beyond 34 completed weeks of gestation by at least 10%. Nested within the trial, we will evaluate cytokine levels in the maternal circulation and decidua. We plan to randomise 900 women (450 participants in each arm): To detect a 10% difference in live birth beyond 34 weeks, for an alpha of 5% and power of 80%, 380 women will need to be randomised to each group. However, assuming and adjusting for a worst case scenario of a 15% attrition, the total number of participants required will be 900. The analysis will be by intention to treat, and according to a pre-specified analysis plan. The trial will be co-ordinated by an Accredited Clinical Trials Unit. Twenty one hospitals in the UK will participate in this trial, which will be led by a strong team of researchers with track record in conducting multicentre trials as well as miscarriage, preterm birth and thyroid research. The trial is supported by patients (78 interviewed), Miscarriage Association, British Thyroid Foundation, British Thyroid Association, the RCOG and others. If our study confirms the benefits shown in the existing trials, the NHS can save over #215 million/year.|


Research activity codes: 6.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS
Health categories: REPRODUCTIVE HEALTH AND CHILDBIRTH